
|Articles|November 13, 2012
Celgene Stock Soars on Promising Pancreatic Cancer Drug Data
Advertisement
Celgene, which unexpectedly reported the results late on Friday, did not give details of the extent of the improvement, saying it would do so at a medical meeting in January.
Abraxane is already approved to treat breast and lung cancer and the company will apply for approval from regulators to market the drug to treat pancreatic cancer as well.
Read the full story:
Source: Reuters
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA to Remove Black Box Warnings From HRT, Debate Ensues
2
High Fiber Linked to Fewer Bowel Symptoms in CRC Survivors
3
Risk-Based Contracts May Not Cut Low-Value Care in Medicare Advantage
4
POLY-HF: Polypill Boosts Heart Function, Adherence in Heart Failure
5















































